Journal Mobile Options
Table of Contents
Vol. 55, No. 3-4, 2007
Issue release date: October 2007
Neuropsychobiology 2007;55:163–166
(DOI:10.1159/000106475)

Increased Incidence of Pituitary Microadenomas in Suicide Victims

Furgal-Borzych A. · Lis G.J. · Litwin J.A. · Rzepecka-Wozniak E. · Trela F. · Cichocki T.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Current data suggest an influence of the hypothalamic-pituitary-adrenal axis on suicidal behavior. The frequency of pituitary adenomas in suicide victims has not yet been investigated. Objectives: The aim of this study was to assess whether the incidence of pituitary adenomas is correlated with suicide. Methods: Serial sections of 151 human pituitary glands obtained upon autopsy were examined microscopically. The glands were collected from 70 suicide victims and 81 subjects whose deaths were classified as unexpected or accidental (nonsuicidal group). The sections were stained with hematoxylin-eosin and the presence of adenoma was confirmed by immunostaining for collagen III. Results: In the suicidal group, pituitary microadenomas were found in 32 cases (47.7%), while in the nonsuicidal group microadenomas were detected in 15 cases (18.3%). The observed difference was statistically significant (p = 0.0003). The relative risk ratio of suicide in persons with pituitary adenomas was estimated at 1.9. Logistic regression analysis in a model controlled for age and sex showed that microadenomas constituted a unique risk factor in this model. The immunohistochemical phenotyping revealed a higher percentage of immunopositive (secreting) microadenomas in the nonsuicidal group as compared to the suicidal group (80.0 vs. 59.38%) and a predominance of growth hormone-secreting microadenomas in both groups. However, these differences as well as differences in the hormonal profiles of microadenomas between the groups were not significant. Conclusions: These results suggest that pituitary adenomas belong to suicide risk factors.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Pitchot W, Reggers J, Pinto E, Hansenne M, Fuchs S, Picard S, Ansseau M: Reduced dopaminergic activity in depressed suicides. Psychoneuroendocrinology 2001;26:331–335.
  2. Van Heeringen K: The neurobiology of suicide and suicidality. Can J Psychiatry 2003;48:292–300.

    External Resources

  3. Pfennig A, Kunzel HE, Kern N, Ising M, Majer M, Fuchs B, Ernst G, Holsboer F, Binder EB: Hypothalamus-pituitary-adrenal system regulation and suicidal behavior in depression. Biol Psychiatry 2005;57:336–342.
  4. Corrigan MH, Gillette GM, Quade D, Garbutt JC: Panic, suicide, and agitation: independent correlates of the TSH response to TRH in depression. Biol Psychiatry 1992;31:984–992.
  5. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE: The prevalence of pituitary adenomas: a systematic review. Cancer 2004;101:613–619.
  6. Gsponer J, De Tribolet N, Deruaz JP, Janzer R, Uske A, Mirimanoff RO, Reymond MJ, Rey F, Temler E, Gaillard RC, Gomez F: Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients. Medicine (Baltimore) 1999;78:236–269.
  7. Malone KM, Corbitt EM, Li S, Mann JJ: Prolactin response to fenfluramine and suicide attempt lethality in major depression. Br J Psychiatry 1996;168:324–329.
  8. Jones TJ, Hallworth MJ: Postmortem prolactin as a marker of antemortem stress. J Clin Pathol 1999;52:749–751.
  9. Kellner R, Buckman MT, Fava GA, Pathak D: Hyperprolactinemia, distress, and hostility. Am J Psychiatry 1984;141:759–763.
  10. Coryell W, Schlesser M: The dexamethasone suppression test and suicide prediction. Am J Psychiatry 2001;158:748–753.
  11. Coryell W, Young E, Carroll B: Hyperactivity of the hypothalamic-pituitary-adrenal axis and mortality in major depressive disorder. Psychiatry Res 2006;142:99–104.
  12. Merali Z, Kent P, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, Bedard T, Anisman H: Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. Biol Psychiatry 2006;59:594–602.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00